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Heterogeneous trends in burden of heart disease mortality by 
subtypes in the United States, 1999-2018: observational  
analysis of vital statistics
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AbstrAct
Objective
To describe trends in the burden of mortality due 
to subtypes of heart disease from 1999 to 2018 to 
inform targeted prevention strategies and reduce 
disparities.
Design
Serial cross sectional analysis of cause specific heart 
disease mortality rates using national death certificate 
data in the overall population as well as stratified by 




12.9 million decedents from total heart disease (49% 
women, 12% black, and 19% <65 years old).
Main OutcOMe Measures
Age adjusted mortality rates (AAMR) and years of 
potential life lost (YPLL) for each heart disease 
subtype, and respective mean annual percentage 
change.
results
Deaths from total heart disease fell from 752 192 
to 596 577 between 1999 and 2011, and then 
increased to 655 381 in 2018. From 1999 to 2018, 
the proportion of total deaths from heart disease 
attributed to ischemic heart disease decreased from 
73% to 56%, while the proportion attributed to heart 
failure increased from 8% to 13% and the proportion 
attributed to hypertensive heart disease increased 
from 4% to 9%. Among heart disease subtypes, AAMR 
was consistently highest for ischemic heart disease in 
all subgroups (race-sex, age, and region). After 2011, 
AAMR for heart failure and hypertensive heart disease 
increased at a faster rate than for other subtypes. 
The fastest increases in heart failure mortality were 
in black men (mean annual percentage change 4.9%, 
95% confidence interval 4.0% to 5.8%), whereas 
the fastest increases in hypertensive heart disease 
occurred in white men (6.3%, 4.9% to 9.4%). The 
burden of years of potential life lost was greatest from 
ischemic heart disease, but black-white disparities 
were driven by heart failure and hypertensive heart 
disease. Deaths from heart disease in 2018 resulted 
in approximately 3.8 million potential years of life lost.
cOnclusiOns
Trends in AAMR and years of potential life lost for 
ischemic heart disease have decelerated since 
2011. For almost all other subtypes of heart disease, 
AAMR and years of potential life lost became 
stagnant or increased. Heart failure and hypertensive 
heart disease account for the greatest increases 
in premature deaths and the largest black-white 
disparities and have offset declines in ischemic heart 
disease. Early and targeted primary and secondary 
prevention and control of risk factors for heart 
disease, with a focus on groups at high risk, are 
needed to avoid these suboptimal trends beginning 
earlier in life.
Introduction
The age adjusted mortality rate (AAMR) for heart 
diseases in the US declined by more than 50% in the 
second half of the 20th century from a peak of 307 
per 100 000 in 1950.1 This fall was predominantly 
driven by rapid declines in mortality from ischemic 
heart disease, as a result of progress in prevention (for 
example, decline in smoking rates) and evidence based 
treatments (for example, statins, antiplatelet agents, 
and antihypertensives).1-3 Although mortality rates 
continued to decline after 2000,4 recent data showed 
that the AAMR for heart disease plateaued in 2011.2 5 6 
Furthermore, some indicators now suggest a reversal 
in the trend, with increasing rates of death from heart 
disease in certain population subgroups such as 
middle aged Americans,7 8 as well as by region in the 
US,9 thus undoing decades of progress in prevention 
and treatment of heart disease and contributing to 
decreases in overall life expectancy in the US.10 Similar 
trends have also been observed in other high income 
countries.11
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WhAt Is AlreAdy knoWn on thIs topIc
Surveillance data from national death certificates show that declines in total 
heart disease mortality in the US have slowed since 2011
Advances in medical and surgical therapies may have led to heterogeneous 
patterns in death rates for specific subtypes of heart disease
Detailed understanding of how mortality due to subtypes of heart disease 
contributes to total heart disease mortality patterns will inform implementation 
of multilevel prevention interventions
WhAt thIs study Adds
Increases in heart failure and hypertensive heart disease mortality occurred 
parallel to declines in ischemic heart disease mortality, resulting in 3.5 million 
years of potential life lost from total heart disease in 2018
Black men had the highest burden of mortality from leading subtypes of heart 
disease
However, the greatest increases midlife mortality due to heart disease subtypes 
were observed in black women (heart failure) and white women (hypertensive 
heart disease)
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However, subtypes of heart disease are heterogeneous 
in their pathophysiology and contribution to 
preventable deaths. Recent analysis indicates that the 
stagnation in total heart disease mortality rates in 2011 
was driven by a slowing in the decline of deaths from 
ischemic heart disease and increases in heart failure 
mortality rates.12 13 Further detailed characterization 
of patterns in deaths for each subtype of heart disease 
across subgroups that are responsible for the observed 
changes in heart disease mortality rates would in-
form targeted prevention and treatment efforts. We 
therefore investigated trends across race-sex, age, 
and geographic groups in cause specific deaths from 
heart disease (ischemic heart disease, heart failure, 
hypertensive heart disease, valvular heart disease, 
arrhythmia, pulmonary heart disease, and other heart 
diseases) using national death certificate data from 
1999 to 2018. We calculated complementary metrics 
to quantify deaths due to subtypes of heart disease, 
including age adjusted mortality rates (AAMR), years of 
potential life lost (YPLL), and mean annual percentage 
changes in these metrics, for heart disease subtypes to 
better evaluate the burden of avoidable heart disease 
mortality.
Methods
Using mortality data from the Wide-Ranging Online 
Data for Epidemiologic Research (WONDER) database 
of death certificates from the Centers for Disease 
Control and Prevention (CDC), we identified all 
decedents from 1999 to 2018 by ICD-10 (international 
classification of diseases, 10th revision) code with 
an underlying (main) cause of death of total heart 
disease, which comprised heart disease subtypes 
classified as ischemic heart disease (ICD-10 code 
I20-I25), heart failure (I50), hypertensive heart 
disease (I11, I13), valvular heart disease (I34-I38), 
arrhythmia (I47-I49), pulmonary heart disease 
(I26-I28), and other heart diseases (I00-I09, I30-I33, 
I40-I46, I51, which includes acute and chronic 
rheumatic heart disease, pericardial diseases, acute 
myocarditis, and unspecified cardio myopathy and 
cardiac arrest not otherwise defined). The CDC 
internally recoded deaths classified using ICD-9 codes 
before local implementation of ICD-10 by using ICD-
10 codes for the WONDER database. The database 
includes all death certificates filed in the US, and less 
than 0.01% of death certificates are missing data on 
age of decedent. No data were suppressed owing to 
low counts in subgroup analyses. We calculated the 
percentage of each heart disease subtype’s overall 
contribution to total heart disease.
We examined trends in the overall population (all 
race groups), separately by race-sex groups (black 
women, white women, black men, white men), and 
stratified by age at death (<45 years, 45-64 years, ≥65 
years) for the main analysis. We categorized decedents 
by “race” in accordance with standard death certificate 
designations and categorizations of decedents in vital 
statistics in the US during the study period. The “black” 
categorization is used on death certificates in the US 
and designates only race and not ethnicity. The race-
sex analysis was limited to black and white people 
because other race/ethnic groups (Asian Americans, 
Native Americans, Hispanic Americans) were either 
too small (Native Americans) or less reliably identi-
fied (Hispanic American, Asian Americans) in CDC 
WONDER.14 15 In supplemental analyses, we evaluated 
trends in heart disease subtypes by census region 
(North east, Midwest, South, and West) and county 
level urbanization (rural: micropolitan, non-core 
regions; urban: large central metro, large fringe metro, 
medium metro, small metro regions).16
We calculated AAMR per 100 000 population 
adjusted using the 2000 US standard population 
overall and stratified by race-sex, age, and geographic 
subgroups.15 We calculated YPLL by using standard 
methods previously used, with average life expectancy 
as the reference age for the main analysis.17 18 YPLL 
captures the burden of premature mortality by placing 
a greater weight on deaths that occur at younger ages. 
Specifically, we obtained average life expectancy 
between 1999 and 2018 for the overall US population 
(78 years) from US vital statistics reports and applied 
it as the reference age to calculate YPLL overall and in 
race-sex subgroups.19 20 We obtained life expectancies 
in race-sex subgroups (77 years for black women, 
81 years for white women, 71 years for black men, 
and 76 years for white men) and used them in YPLL 
calculations to quantify the absolute number of years 
of potential life lost by decedents in the US during the 
study period in the context of current life expectancy 
estimates. As using race-sex specific life expectancies 
to calculate YPLL may not adequately account for 
underlying disparities in life expectancy between 
groups, a secondary analysis calculated YPLL with 
a reference age of 85 years applied to all groups, for 
a standardized assessment of YPLL. For each year 
of analysis, we calculated YPLL by multiplying the 
number of deaths from heart disease subtypes by 
the difference between the reference age and the 
midpoint age at death within each 5 year age group in 
each of a series of 5 year age group decrements from 
the reference age. We divided this result by the total 
5 year age group population and then multiplied by 
100 000 to obtain YPLL per 100 000 population. After 
age standardizing YPLL with the 2000 US standard 
population, the sum of YPLL in each 5 year age group 
provided cause specific YPLL per 100 000 in the total 
population and race-sex subgroups, for each year of 
analysis. We calculated YPLL for total heart disease, 
ischemic heart disease, heart failure, and hypertensive 
heart disease. Because of relatively few deaths due to 
other heart diseases subtypes, we also calculated YPLL 
for a category of “remainder heart disease subtypes” 
that comprised the remainder of the underlying heart 
disease cause of death codes. We also calculated YPLL 
for total heart disease from a reference age of 85 years 
for the overall population and all race-sex subgroups, 
to provide a comparison of the burden of YPLL that 
is not dependent on underlying differences in life 
expectancy by race or sex.
 on 17 A










J: first published as 10.1136/bm
j.m






the bmj | BMJ 2020;370:m2688 | doi: 10.1136/bmj.m2688 3
We characterized temporal trends in AAMR and YPLL 
by fitting log-linear regression models using Joinpoint 
Regression Program (National Cancer Institute). We 
used log transformed data, as certain subtypes of 
heart disease had relatively few deaths. On the basis 
of previously published methodological guidelines,21 
we applied Joinpoint Regression to identify inflection 
points in the trend of AAMR for total heart disease 
across the study period from 1999 to 2018. These 
guidelines recommend that for trends data containing 
17-21 time points, the analysis should be allowed to 
identify up to three inflection points in trends across 
time.21 Therefore, we allowed the Joinpoint Regression 
statistical software to identify up to three trend 
inflections where significant temporal variation existed 
in the trend (P<0.05), given the inclusion of 20 years of 
data in the current analysis. Fewer than the maximum 
allowed number of inflection points could be identified 
if the magnitude of variation between trends was 
greatest with fewer inflection points. In our analysis, 
one inflection point was identified in the trend of AAMR 
for total heart disease at the year 2011 (consistent with 
previously published trends identified with Joinpoint 
Regression5). We therefore subsequently evaluated 
the temporal intervals between 1999 and 2011 and 
between 2011 to 2018 in all heart disease subtype 
analyses (age, race-sex, regional, and urbanization 
subgroups) to provide a standard comparison.
We then used these temporal intervals for AAMR 
and YPLL in each subgroup analysis to calculate 
mean annual percentage change, weighted to account 
for differences in number and time point of trend 
inflection points in subgroup models. We used the 
Joinpoint Regression statistical software to calculate 
mean annual percentage change from 1999 to 2011 
and from 2011 to 2018 by determining the weighted 
average of the annual percentage change between each 
time point, with weights equal to the length of each 
individual model’s inter-inflection point trend. In other 
words, mean annual percentage changes based on the 
linear trend segments identified are dependent on 
each subgroup model’s number of identified inflection 
points (that is, if a subgroup trend is optimized with no 
inflection points, indicating one linear trend across the 
entire study period from 1999 to 2018, mean annual 
percentage change before and after 2011 would be the 
same).
As a supplemental analysis, we evaluated AAMR 
and YPLL for heart failure as a contributing cause of 
cardiovascular deaths by using the CDC WONDER 
multiple cause of death files, to more broadly 
characterize and quantify the burden of heart failure 
related mortality. These metrics were calculated 
as previously described, for deaths defined as any 
mention of heart failure (ICD-10 code I50) on death 
certificates with cardiovascular disease (ICD-10 code 
I00-I78) listed as underlying cause of death.22
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for design or execution 
of the study. No patients were asked to advise on 
interpretation or writing up of results. There are no 
plans to disseminate the results of the research to study 
participants or the relevant patient community as this 




Between 1999 and 2018, 12.9 million deaths from total 
heart disease occurred in the overall US population in 
all race groups, of which 49.1% (6.3 million) were in 
women, 11.6% (1.5 million) were in black people, and 
86.2% (11.1 million) were in white people. In total, 
752 192 deaths from total heart disease occurred in 
1999, 596 577 in 2011, and 655 381 in 2018. From 
1999 to 2018, ischemic heart disease accounted 
for a declining proportion of total heart disease 
deaths (from 73.0% to 55.8%), alongside increasing 
proportions of total heart disease deaths from heart 
failure (from 7.6% to 12.8%), hypertensive heart 
disease (3.6% to 9.2%), valvular heart disease (2.7% 
to 3.7%), arrhythmia (2.5% to 5.6%), pulmonary heart 
disease (1.8% to 2.8%), and other heart disease (8.7% 
to 10.3%) (fig 1 and supplementary table A). Overall, 
2.6% of decedents were under 45 years old, 16.3% 
were 45-64 years old, and 81.2% were aged 65 years 
or older. The proportion of deaths among middle aged 
decedents (45-64 years) increased from 13.7% in 1999 
to 17.3% in 2018.
trends in heart disease mortality rates in overall us 
population
AAMR for total heart disease declined from 266.5 
(95% confidence interval 265.8 to 267.1) per 100 000 
in 1999 to 163.6 (163.2 to 164.0) per 100 000 in 2018 
(table 1). Trends in declines in AAMR (that is, mean 
annual percentage change) for total heart disease 
decelerated, from −3.7% (95% confidence interval 
−3.8% to −3.5%) per year before 2011 to −0.7% 
(−1.1% to −0.3%) per year after 2011 for all decedents. 
AAMR for ischemic heart disease declined from 194.6 
(194.1 to 195.1) per 100 000 in 1999 to 109.2 (108.8 
to 109.5) per 100 000 in 2011, but further declined 
only to 90.9 (90.6 to 91.2) per 100 000 in 2018. Mean 
annual percentage change in ischemic heart disease 
mortality slowed from −4.7% (−5.1% to −4.2%) per 
year before 2011 to −2.6% (−3.3% to −2.0%) per 
year after 2011. Trends in heart failure mortality 
rates reversed and increased (overall mean annual 
percentage change −1.7% (–2.5% to −0.8%) per year 
before 2011 compared with 3.5% (2.6% to 4.5%) per 
year after 2011), reflecting a decline in AAMR from 
20.3 (20.1 to 20.4) per 100 000 in 1999 to 16.9 (16.8 
to 17.1) per 100 000 in 2011, which was followed 
by a rise to 20.8 (20.7 to 20.9) per 100 000 again by 
2018. Overall, the mean annual percentage change in 
hypertensive heart disease mortality rates accelerated 
from 1.2% (0.7% to 1.7%) per year before 2011 to 
4.8% (3.3% to 6.3%) per year after 2011. The absolute 
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numbers of deaths from and AAMR for valvular 
heart disease, arrhythmia, and pulmonary heart 
disease were relatively low compared with ischemic 
heart disease, heart failure, and hypertensive heart 
disease. Whereas AAMR for valvular heart disease 
decreased from 2011 to 2018 (from 6.7 (6.6 to 6.8) to 
6.1 (6.0 to 6.2) per 100 000; mean annual percentage 
change −1.6% (–2.8% to −0.4%) per year), AAMR for 
arrhythmia and pulmonary heart disease increased to 
9.1 (9.0 to 9.2) per 100 000 and 4.6 (4.6 to 4.7) per 
100 000, respectively.
In secondary analyses, trends in AAMR for heart 
disease subtypes were similar by census region in 
the US, although AAMRs for total and heart disease 
subtypes were highest in the American South com-
pared with other US census regions and generally 
higher in rural counties compared with urban counties 
(supplementary figures A and B, respectively).
trends in heart disease mortality rates by race and 
sex
Black men had the highest AAMR for total heart disease 
(260.3 (205.6 to 207.1) per 100 000 in 2018), which 
was reflected primarily in high AAMR for ischemic 
heart disease (138.1 (136.2 to 139.9) per 100 000 in 
2018), heart failure (28.9 (28.0 to 29.8) per 100 000), 
and hypertensive heart disease (35.3 (34.4 to 36.3) per 
100 000). Trends in AAMR for total heart disease and 
ischemic heart disease slowed similarly after 2011 in 
black and white men and women (fig 2; supplementary 
table B). All race-sex groups showed a reversal of heart 
failure mortality trends after 2011. Notably, after 
2011 mean annual percentage change in heart failure 
mortality rates was higher in black men (4.9% (4.0% 
to 5.8%) per year) than in black women, white men, 
and white women. Acceleration of hypertensive heart 
disease mortality rates was highest in white women 
(mean annual percentage change 5.6% (4.3% to 7.0%) 
per year) and white men (6.3% (4.9% to 9.4%) per 
year) after 2011. Although mean annual percentage 
change in hypertensive heart disease mortality rates 
was lower in black women and black men, absolute 
AAMR was higher in black than in white decedents.
trends in heart disease mortality rates by age
AAMR was lowest for decedents under 45 years old at 
time of death across the study period (table 2). In this 
youngest age stratum, AAMR for total heart disease was 
8.7 (8.6 to 8.9) per 100 000 in 2018, predominantly 
attributable to ischemic heart disease (AAMR 3.2 
(3.1 to 3.3) per 100 000 in 2018) and hypertensive 
heart disease (1.4 (1.4 to 1.5) per 100 000). AAMR for 
hypertensive heart disease continued to worsen but 
decelerated from a mean annual percentage change 
of 4.8% (3.7% to 5.9%) per year before 2011 to 2.3% 
(1.9% to 2.8%) per year after 2011. However, mean 
annual percentage change in heart failure mortality 
rates accelerated after 2011, and mean annual 
percentage change in valvular heart disease indicated 
a reversal from decreasing AAMR to increasing AAMR. 
Secondary analysis of AAMR patterns in race-sex 
groups in decedents age under 45 years is shown in 
supplementary table C.
For decedents aged 45-64 years at time of death 
(table 2), AAMR for total heart disease declined 
between 1999 and 2011 (from 164.1 (163.2 to 165.2) 
to 121.0 (120.2 to 121.7) per 100 000; mean annual 
percentage change −2.5% (–2.8% to −2.2%) per year) 
but remained generally unchanged between 2011 and 
2018 (to 122.3 (121.6 to 123.0) per 100 000; mean 
annual percentage change 0.2% (–0.1 to 0.4%) per 
year). AAMR was highest for ischemic heart disease 
table 1 | trends in age adjusted mortality rates attributed to total heart disease and each subtype of heart disease in overall us population, 1999-2018
Heart disease subtype
age adjusted mortality rate per 100 000 (95% ci) Mean annual percentage change (95% ci)*
1999 (n=725 192) 2011 (n=596 577) 2018 (n=655 381) 1999-2011 2011-18
total heart disease 266.5 (265.8 to 267.1) 173.7 (173.3 to 174.2) 163.6 (163.2 to 164.0) −3.7 (−3.8 to −3.5)† −0.7 (−1.1 to −0.3)†
ischemic heart disease 194.6 (194.1 to 195.1) 109.2 (108.8 to 109.5) 90.9 (90.6 to 91.2) −4.7 (−5.1 to −4.2)† −2.6 (−3.3 to −2.0)†
Heart failure 20.3 (20.1 to 20.4) 16.9 (16.8 to 17.1) 20.8 (20.7 to 20.9) −1.7 (−2.5 to −0.8)† 3.5 (2.6 to 4.5)†
Hypertensive heart disease 9.6 (9.5 to 9.7) 10.8 (10.7 to 10.9) 15.1 (15.0 to 15.2) 1.2 (0.7 to 1.7)† 4.8 (3.3 to 6.3)†
valvular heart disease 7.2 (7.1 to 7.3) 6.7 (6.6 to 6.8) 6.1 (6.0 to 6.2) −0.4 (−0.6 to −0.1)† −1.6 (−2.8 to −0.4)†
arrhythmia 6.7 (6.6 to 6.8) 8.2 (8.1 to 8.3) 9.1 (9.0 to 9.2) 1.7 (1.4 to 2.0)† 1.7 (1.4 to 2.0)†
Pulmonary heart disease 4.8 (4.8 to 4.9) 4.2 (4.1 to 4.3) 4.6 (4.6 to 4.7) −0.9 (−2.1 to 0.2) 1.5 (1.0 to 1.9)†
Other heart disease 23.2 (23.0 to 23.4) 17.8 (17.6 to 17.9) 17.1 (16.9 to 17.2) −2.0 (−2.3 to −1.6)† −0.7 (−1.0 to −0.4)†
*Mean annual percentage change shown for age adjusted mortality rates for specified time range.




























































Fig 1 | Proportion of total heart disease deaths attributable to each heart disease 
subtype in us, 1999-2018. Proportion of heart disease deaths due to ischemic heart 
disease decreased, whereas proportion of heart disease deaths due to all other causes 
increased; these were predominantly from heart failure and hypertensive heart disease, 
which were the second and third leading causes of heart disease death. actual number 
of deaths are shown in supplementary table a
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(73.1 (72.6 to 73.7) per 100 000 in 2018), hypertensive 
heart disease (15.2 (15.0 to 15.5) per 100 000 in 
2018), and heart failure (6.8 (6.7 to 7.0) per 100 000 
in 2018). Mean annual percentage change in ischemic 
heart disease mortality rates decelerated after 2011 but 
accelerated for hypertensive heart disease mortality 
rates (mean annual percentage change 3.0% (2.6% to 
3.5%) per year) and heart failure mortality rates (5.7% 
(4.4% to 7.0%) per year). Secondary analysis of AAMR 
patterns in race-sex groups in decedents aged 45-64 
years is shown in supplementary table D.
Decedents aged 65 years or over had the highest 
AAMR for all types of heart disease compared with 
younger decedents (table 2). AAMR for total heart 
disease declined from 1767.0 (1762.5 to 1771.4) per 
100 000 in 1999 to 1115.6 (1112.4 to 1118.8) per 
100 000 in 2011 (mean annual percentage change 
−3.7% (–4.3 to −3.1%) per year), but further declined 
only to 1034.6 (1031.7 to 1037.4) per 100 000 
between 2011 to 2018 (mean annual percentage 
change −1.1% (–1.6% to −0.6%) per year). Similarly 
to mortality patterns at younger ages, mortality rate 
trends for hypertensive heart disease accelerated 
after 2011, and heart failure trends reversed from 
decreasing to increasing AAMR. Secondary analysis of 
AAMR patterns in race-sex groups in decedents age 65 
years or over is shown in supplementary table E. In the 
subset of deaths between age 65 and 84 years, similar 
mortality patterns were observed (supplementary 
table F).
trends in years of potential life lost due to subtypes 
of heart disease
Estimated YPLL per 100 000 population is shown 
in table 3 and supplementary figure C. YPLL due to 
total heart disease in the overall US population was 
estimated to be 1068 years per 100 000 population in 
2018. Of all the heart disease subtypes, YPLL in 2018 
was highest for ischemic heart disease (578 years per 
100 000), followed by hypertensive heart disease (132 
years per 100 000) and then heart failure (64 years 
per 100 000). YPLL due to ischemic heart disease was 
similar in white and black men but 1.3-fold higher 
in black women than in white women. For ischemic 
heart disease, mean annual percentage change in 
YPLL decelerated from −3.8% (−3.9% to −3.7%) per 
year overall before 2011 to −1.6% (−1.8% to −1.4%) 
per year after 2011, with similar trends in all race-
sex groups. YPLL due to hypertensive heart disease 
was 2.9-fold higher in black women (219 years per 
100 000) and 2.3-fold higher in black men (305 per 
100 000) compared with white women and men in 
2018, respectively. However, faster increases in YPLL 
over the study period were observed in white women 
(mean annual percentage change 4.2% (0.9% to 7.7%) 



























































































Fig 2 | age adjusted mortality rates for total heart disease and leading heart disease subtypes in black and white women and men in us, 1999-
2018. age adjusted mortality rates shown for total heart disease, ischemic heart disease, heart failure, and hypertensive heart disease in black and 
white women and men. Dashed line represents temporal inflection point in total heart disease identified by joinpoint regression. average annual 
percentage changes in age adjusted mortality rates before and after 2011 are listed in supplementary table b
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3.5%) per year after 2011). For heart failure, YPLL 
changed from either decreasing or stagnant before 
2011 to increasing after 2011. Black women and 
men had a twofold higher YPLL due to heart failure 
compared with white women and men, with highest 
mean annual percentage change in YPLL in black 
women (5.8% (4.5% to 7.2%) per year) and black men 
(6.6% (5.0% to 8.3%) per year).
We also calculated YPLL due to total heart disease 
from the average US life expectancy and from age 85 
as the reference age applied to all race-sex subgroups 
(supplementary tables G and H). We observed similar 
patterns in both of these analyses compared with YPLL 
from race-sex specific life expectancies, in which black 
women and men had higher YPLL than white women 
and men. Declining trends in YPLL from 1999 to 2011 
were statistically significant. Trends in all subgroups 
slowed or stagnated from 2011 to 2018.
Finally, in secondary analysis, we assessed AAMR 
and YPLL from heart failure as a contributing cause 
of cardiovascular death (supplementary table I). We 
observed similar patterns compared with heart failure 
as an underlying cause of death: AAMR and YPLL 
trends reversed from decreasing between 1999 to 2011 
to increasing after 2011 through 2018 for all race-sex 
and age groups.
Supplementary table J provides a summary of 
contemporary heart disease mortality statistics in the 
overall population by each of the metrics (total number 
of decedents by subtype, percentage contribution of 
each subtype to total heart disease deaths, AAMR by 
subtype, and YPLL by subtype) for 2018.
discussion
Changing patterns in mortality due to heart disease 
subtypes in the US are reflected overall by a plateau in 
age adjusted mortality rate for total heart disease since 
2011, within which deceleration of mortality rates for 
ischemic heart disease are coupled with increases in 
mortality rates for heart failure and hypertensive heart 
disease in all race-sex groups. In particular, black men 
had both the highest AAMR and the fastest increase in 
mortality rates for heart failure compared with other 
groups. Although mortality rates for hypertensive heart 
disease increased for all race-sex groups, the fastest 
increases in AAMR for hypertensive heart disease were 
observed in white women and men between 2011 and 
2018. However, AAMR for hypertensive heart disease 
remained about twice as high in black as in white 
populations by 2018.
Our estimates of the burden of heart disease 
expressed as YPLL translate into approximately 
table 2 | trends in age adjusted mortality rates attributed to total heart disease and each subtype of heart disease by age at death in overall us 
population, 1999-2018
Heart disease subtype and 
age at death
age adjusted mortality rates per 100 000 (95% ci) Mean annual percentage change (95% ci)*
1999 2011 2018 1999-2011 2011-18
Total heart disease
<45 years 10.3 (10.1 to 10.4) 9.0 (8.9 to 9.2) 8.7 (8.6 to 8.9) −1.0 (−1.5 to −0.5)† −0.3 (−0.7 to 0.1)
45-64 years 164.1 (163.1 to 165.2) 121.0 (120.2 to 121.7) 122.3 (121.6 to 123.0) −2.5 (−2.8 to −2.2)† 0.2 (−0.1 to 0.4)
≥65 years 1767.0 (1762.5 to 1771.4) 1115.6 (1112.4 to 1118.8) 1034.6 (1031.7 to 1037.4) −3.7 (−4.3 to −3.1)† −1.1 (−1.6 to −0.6)†
Ischemic heart disease
<45 years 4.9 (4.8 to 5.0) 3.8 (3.7 to 3.9) 3.2 (3.1 to 3.3) −1.9 (−2.6 to −1.3)† −2.3 (−2.7 to −1.9)†
45-64 years 121.1 (120.2 to 121.9) 79.3 (78.7 to 79.9) 73.1 (72.6 to 73.7) −3.4 (−3.6 to −3.3)† −1.4 (−1.6 to −1.2)†
≥65 years 1301.6 (1297.7 to 1305.4) 704.7 (702.2 to 707.3) 573.8 (571.7 to 575.9) −4.9 (−5.4 to −4.4)† −3.0 (−3.4 to −2.3)†
Heart failure
<45 years 0.2 (0.2 to 0.3) 0.3 (0.3 to 0.3) 0.4 (0.4 to 0.5) 2.8 (0.5 to 5.0)† 5.1 (2.7 to 7.6)†
45-64 years 4.8 (4.6 to 4.9) 4.5 (4.4 to 4.7) 6.8 (6.7 to 7.0) −0.6 (−1.2 to −0.1)† 5.7 (4.4 to 7.0)†
≥65 years 150.8 (149.5 to 152.2) 124.5 (123.5 to 125.6) 150.4 (149.3 to 151.5) −1.7 (−2.6 to −0.9)† 3.3 (2.4 to 4.3)†
Hypertensive heart disease
<45 years 0.7 (0.7 to 0.8) 1.2 (1.1 to 1.2) 1.4 (1.4 to 1.5) 4.8 (3.7 to 5.9)† 2.3 (1.9 to 2.8)†
45-64 years 8.1 (7.9 to 8.3) 12.1 (11.8 to 12.3) 15.2 (15.0 to 15.5) 3.9 (2.1 to 5.6)† 3.0 (2.6 to 3.5)†
≥65 years 57.6 (56.8 to 58.4) 58.0 (57.3 to 58.7) 85.5 (84.7 to 86.3) 0.3 (−0.2 to 0.8) 5.4 (3.6 to 7.2)†
Valvular heart disease
<45 years 0.3 (0.3 to 0.4) 0.2 (0.2 to 0.2) 0.3 (0.3 to 0.3) −3.9 (−6.0 to −1.8)† 7.1 (1.4 to 13.2)†
45-64 years 2.5 (2.4 to 2.6) 2.1 (2.0 to 2.2) 2.2 (2.1 to 2.3) −1.6 (−3.2 to 0.1) 1.0 (−2.0 to 4.0)
≥65 years 51.0 (50.2 to 51.7) 48.1 (47.4 to 48.8) 42.7 (42.1 to 43.3) −0.3 (−0.5 to 0.0)† −1.9 (−3.2 to −0.6)†
Arrhythmia
<45 years 0.4 (0.4 to 0.4) 0.4 (0.4 to 0.4) 0.4 (0.3 to 0.4) −0.3 (−1.0 to 0.4) −0.3 (−1.0 to 0.4)
45-64 years 3.2 (3.0 to 3.3) 3.4 (3.3 to 3.5) 3.9 (3.8 to 4.1) 0.5 (−0.9 to 2.0) 2.2 (1.0 to 3.4)†
≥65 years 45.7 (45.0 to 46.4) 56.6 (55.9 to 57.3) 63.1 (62.4 to 63.8) 1.8 (1.5 to 2.1)† 1.8 (1.5 to 2.1)†
Pulmonary heart disease
<45 years 0.9 (0.8 to 0.9) 0.7 (0.6 to 0.7) 0.7 (0.7 to 0.8) −1.8 (−3.0 to −0.6)† 0.3 (−0.9 to 1.5)
45-64 years 4.6 (4.5 to 4.8) 4.0 (3.8 to 4.1) 4.3 (4.2 to 4.5) −1.8 (−2.5 to −1.0)† 1.4 (0.4 to 2.4)†
≥65 years 25.7 (25.2 to 26.2) 23.0 (22.5 to 23.4) 25.3 (24.8 to 25.7) −0.7 (−2.1 to 0.7) 1.7 (1.1 to 2.2)†
Other heart disease
<45 2.8 (2.7 to 2.9) 2.4 (2.3 to 2.5) 2.4 (2.3 to 2.4) −1.3 (−1.7 to −1.0)† −0.1 (−1.0 to 0.8)
45-64 19.8 (19.4 to 20.2) 15.6 (15.3 to 15.8) 16.6 (16.4 to 16.9) −1.9 (−2.6 to −1.2)† 0.9 (0.5 to 1.4)†
≥65 134.5 (133.3 to 135.8) 100.7 (99.7 to 101.7) 93.8 (92.9 to 94.6) −2.2 (−2.6 to −1.7)† −1.0 (−1.3 to −0.6)†
*Mean annual percentage change shown for age adjusted mortality rates for specified time range.
†Indicates that mean annual percentage change is significantly different from zero (P<0.05).
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3.5 million potential years of life lost due to total 
heart disease in 2018, but this burden was borne 
disproportionately in different race-sex groups and 
attributed to different heart disease subtypes. Although 
overall YPLL due to total heart disease declined across 
the study period, premature mortality evaluated by 
YPLL increased for two of the top three subtypes of 
heart disease deaths: hypertensive heart disease 
and heart failure, reflected by an 80% and a 31% 
increase in YPLL from hypertensive heart disease and 
heart failure, respectively, between 1999 and 2018. 
Whereas AAMR was higher for heart failure than for 
hypertensive heart disease, YPLL due to hypertensive 
heart disease was higher, indicating that hypertensive 
heart disease related deaths are occurring at younger 
ages. AAMR for less common causes of heart disease 
(arrhythmia, pulmonary heart disease, and other heart 
disease) was either stagnant or increased from 2011 
to 2018. Valvular heart disease was the only subtype 
for which declines in mortality rates accelerated after 
2011, although the relative burden of deaths from 
valvular heart disease remained low.
comparison with other studies
These findings align with recent data showing 
contemporaneous slowing in the decline of mortality 
rates for cardiometabolic disease and recent sur-
veillance of heart disease mortality showing that the 
growth in the population of older Americans aged 65 
years or over during this time was associated with an 
increase in the number of deaths from heart disease, 
despite a stagnant or slowly declining AAMR.6 13 Our 
results build on these reports by providing broader 
and more detailed mortality patterns for the range of 
heart disease subtypes as underlying cause of death, 
particularly highlighting the rapid growth and high 
burden of death overall from hypertensive heart 
disease, increasing mortality rates for heart failure and 
hypertensive heart disease at younger ages reflected 
in a high magnitude of YPLL from these causes, and 
worrisome patterns in mortality from arrhythmia 
and pulmonary heart disease. These findings likely 
represent a combination of changing patterns of 
incidence and survival for heart disease over the past 
two decades.
Although overall declines in total heart disease 
mortality may be attributed to improved diagnosis 
and management over the past decades, the observed 
recent patterns of heart disease mortality overall may 
be due to the growing burden of cardiometabolic 
risk factors for heart disease. Obesity, diabetes, and 
hypertension likely play a sizeable role in the observed 
changes in recent mortality rates for heart disease in 
the US, where the prevalence of obesity now exceeds 
table 3 | trends in age standardized years of potential life lost per 100 000 population due to total heart disease and each subtype of heart disease in 
overall population and race-sex subgroups in the us, 1999-2018
Heart disease subtype and subgroup
Years of potential life lost (per 100 000 population) Mean annual percentage change (95% ci)*
1999 2011 2018 1999-2011 2011-18
total heart disease
Overall 1494 1080 1068 −2.7 (−2.9 to −2.6)† 0.1 (−0.2 to 0.4)
Black women 1824 1215 1210 −3.5 (−3.8 to −3.3)† −0.1 (−0.7 to 0.6)
White women 1064 754 744 −2.8 (−3.0 to −2.7)† 0.1 (−0.3 to 0.4)
Black men 2183 1549 1602 −2.7 (−3.3 to −2.2)† 0.3 (−0.3 to 0.9)
White men 1677 1244 1205 −2.5 (−2.6 to −2.3)† −0.5 (−0.7 to −0.2)†
ischemic heart disease
Overall 1025 645 578 −3.8 (−3.9 to −3.7)† −1.6 (−1.8 to −1.4)†
Black women 983 543 479 −5.0 (−5.5 to −4.4)† −1.6 (−2.0 to −1.1)†
White women 696 418 373 −4.1 (−4.3 to −3.9)† −1.5 (−1.9 to −1.1)†
Black men 1254 770 716 −3.8 (−4.3 to −3.3)† −1.1 (−1.7 to −0.5)†
White men 1247 816 723 −3.5 (−3.7 to −3.4)† −1.7 (−2.0 to −1.5)†
Heart failure
Overall 49 45 64 −1.0 (−1.7 to −0.3)† 5.5 (4.8 to 6.1)†
Black women 79 70 103 −1.2 (−2.4 to 0.1) 5.8 (4.5 to 7.2)†
White women 50 43 53 −1.4 (−2.9 to 0.1) 3.9 (2.6 to 5.2)†
Black men 71 74 116 0.8 (−0.8 to 2.5) 6.6 (5.0 to 8.3)†
White men 43 39 57 −0.9 (−1.4 to −0.5)† 5.5 (4.5 to 6.6)†
Hypertensive heart disease
Overall 73 107 132 3.4 (2.6 to 4.2)† 3.2 (2.4 to 4.1)†
Black women 210 207 219 0.0 (−0.4 to 0.3) 0.0 (−0.4 to 0.3)
White women 39 57 76 3.4 (2.5 to 4.3)† 4.2 (0.9 to 7.7)†
Black men 237 271 305 1.6 (0.7 to 2.5)† 0.6 (0.2 to 0.9)†
White men 57 105 134 5.4 (4.7 to 6.0)† 3.3 (3.0 to 3.5)†
remainder heart disease subtypes
Overall 346 283 293 −1.6 (−2.0 to −1.3)† 0.5 (−0.7 to 1.7)
Black women 551 394 409 −2.7 (−3.1 to −2.4)† 0.4 (−0.4 to 1.2)
White women 279 236 241 −1.5 (−1.8 to −1.1)† 0.8 (0.2 to 1.3)†
Black men 620 435 465 −2.7 (−3.9 to −1.5)† 0.7 (0.1 to 1.4)†
White men 331 284 291 −1.1 (−1.4 to −0.8)† 0.3 (0.0 to 0.7)
*Mean annual percentage change shown for years of potential life lost for specified time range.
†Indicates that mean annual percentage change is significantly different from zero (P<0.05).
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42%,23 the prevalence of both prediabetes and 
diabetes approaches 50%,24 and the prevalence of 
hypertension is approximately 30%.25 Recent trends in 
assessment of cardiovascular health in the US project 
continued worsening in prevalences of poor quality of 
diet, physical inactivity, obesity, and diabetes in the 
coming decades.26-29 Furthermore, regional differences 
in prevalence of these modifiable risk factors likely 
account for a substantial portion of regional differences 
in the burden of heart disease in the US.30 Such trends 
will likely result in continued increases in mortality 
from heart disease subtypes such as heart failure and 
hypertensive heart disease if current trends continue 
without intervention, given the direct association of 
these subtypes with cardiometabolic risk factors.31-33
The observed differences in heart disease mortality 
by race may partly reflect underlying and pervasive 
disparities in cardiovascular health and burden of 
heart disease.26 Specifically, obesity, diabetes, and 
hypertension in the US remain most prevalent in black 
Americans, and rates of control remain lower in black 
than in white Americans.34 Differences in patterns of 
guideline recommended drug treatment, including drug 
prescription, optimization, and adherence, especially 
for hypertension, likely contribute to racial disparities 
in heart disease morbidity and mortality.35-38 Race is 
used in this analysis according to categorization from 
death certificates and is commonly reported in research 
studies in the US, but it is important to recognize that 
race is a social construct that incorporates more than 
biological differences resulting from ancestral origin 
and is used variably throughout the world.39 A growing 
body of evidence suggests that racial differences in 
cardiovascular health and heart disease mortality are 
in large part representative of avoidable differences 
in many other factors, including a range of social 
determinants of health, socioeconomic status and 
access to care,40 burden of the drug misuse epidemic 
in the US,41 and structural and systemic racism that 
require individual and policy level changes to target 
and reduce persistent health inequities.42 43 We also 
observed differences in heart disease mortality rates 
between men and women, wherein men have higher 
rates of heart disease mortality, and the burden of 
mortality is highest in black men. Sex differences 
may be due to a range of factors, from differences in 
prevalence of risk factors (such as tobacco use44) to 
social determinants such as healthcare use.45
strengths and limitations of study
The principal strength of our analysis is the 
investigation of contemporary nationwide data on 
mortality attributed to leading subtypes of heart 
disease and differences among race-sex, age, and 
geographic subgroups. These data allow for evaluation 
of changes and disparities in patterns of cause specific 
cardiovascular mortality, which contribute to the 
observed increases in total heart disease deaths 
in the past decade and disproportionally burden 
black Americans. Limitations of our analysis include 
incomplete race/ethnicity data. Our investigation 
focuses on the most reliable data available, to 
evaluate trends in white and black subgroups who 
represent approximately 90% of the US population.14 
Given evidence that reporting methods for Hispanic, 
Asian, and Native American ethnicity may lead to 
misclassification and underestimation of mortality 
rates in these groups,46 and that data for disaggregated 
Asian American and Hispanic Americans subgroups 
were not available, these groups were not reported. 
Additionally, death certificate data are subject to 
potential miscoding and misclassification.47 48 How-
ever, these data provide the most comprehensive 
assessment of cause specific heart disease mortality 
rates at a national level. Importantly, these data may 
not reflect the clinical progression of heart diseases, 
such as from ischemic heart disease to heart failure. 
Specifically, as the clinical syndrome of heart failure 
represents a mode of death often attributable to 
hypertension, ischemic heart disease, valvular heart 
disease, or diabetes as the underlying cause,49 our 
primary analysis may underestimate the burden of 
heart failure related mortality and does not identify 
patients with heart failure who had preceding non-fatal 
ischemic heart disease or hypertensive heart disease. 
Notably, similar patterns were seen in our secondary 
analysis evaluating trends in mortality rates for heart 
failure as a contributing cause of cardiovascular death. 
Finally, the “other heart disease” category reflects a 
heterogenous mix of heart diseases that may have 
dissimilar pathophysiology.
conclusions and policy implications
Future research and public health strategies should 
focus on dissemination and implementation 
of interventions that focus on prevention and 
management of heart disease in the populations 
at highest risk to promote equity, clinical quality 
improvement to optimize primary and secondary 
prevention, and policies to improve diet quality and 
facilitate physical activity. For primary prevention, 
simulation modeling for prevention of heart disease 
in high income settings has been conducted in the UK 
and suggests that a strategy of enhanced screening 
for heart disease targeted toward the highest risk 
groups, combined with adoption of population-wide 
structural policies for smoking cessation, reduction 
in sugar sweetened drink consumption, and salt 
reduction in foods, could maximize reductions 
in heart disease mortality and inequalities.50 51 
Additionally, community level interventions tailored 
to tackle risk factors in disproportionately burdened 
race-sex groups have also proven effective in the US, 
such as a barber and pharmacist led intervention 
targeting control of hypertension in black male 
patrons of black owned barbershops.52 Targeting 
such strategies toward younger adults, in particular, 
would likely lead to greater reductions in YPLL 
through the number of premature cardiovascular 
deaths prevented or postponed. Enhanced secondary 
prevention strategies across the life course may 
additionally mitigate mortality across the spectrum 
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of heart disease subtypes. Increasing prescription of 
and adherence to guideline recommended medical 
treatment, as applicable for lipids, for blood pressure, 
for diabetes, with antiplatelet agents,53 or for heart 
failure with reduced ejection fraction,54 may also help 
to change the worrisome observed trends in mortality 
rates. Ultimately, a comprehensive multilevel, multi-
stakeholder approach focused on prevention of 
modifiable risk factors, adherence to evidence based 
secondary prevention strategies, and targeting of 
disproportionately burdened groups is urgently 
needed to curb worrisome trends in deaths from heart 
disease in the US.
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